Amgen

Amgen Inc., headquartered in Thousand Oaks, California, is one of the world’s leading and largest independent biotechnology companies. Founded in 1980, Amgen has been at the forefront of the biotechnology revolution, utilizing advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. The company focuses on discovering, developing, and delivering transformative human therapeutics for patients suffering from serious illnesses, particularly in the core therapeutic areas of oncology, cardiology, bone health, nephrology, and inflammation.

Amgen’s innovative research has led to the development of several blockbuster drugs, including Enbrel (for autoimmune diseases), Prolia (for osteoporosis), and Repatha (for cardiovascular disease), which have significantly improved the lives of millions of patients globally. The organization is renowned for its world-class biological manufacturing capabilities, operating massive, highly automated facilities that produce complex protein-based therapeutics with unparalleled consistency and quality.

Amgen is also a pioneer in the development of novel therapeutic modalities, such as BiTE (Bispecific T-cell Engager) technology, which directs the body’s immune system to target and destroy cancer cells. Through its subsidiary, deCODE genetics in Iceland, Amgen possesses one of the world’s most extensive genetic databases, allowing researchers to identify highly validated drug targets and significantly improve the success rate of clinical trials.

The company’s commitment to scientific excellence is evident in its massive R&D investments and continuous stream of publications in top-tier medical and scientific journals. With a robust pipeline of innovative molecules, Amgen continues to push the boundaries of biotechnology, striving to address massive unmet medical needs and improve global public health.